>> I believe the company [GTCB] has said publicly (and IR told me on the phone) that plan A is to partner ATryn and that this could be announced even before EMEA reaches a decision in early 2005. <<
That’s correct. My reason for emphasizing that ATryn is non-partnered is that the benefits from a partnership agreement constitute a significant potential reward to shareholders in either up-front cash or deferred considerations. This is in contrast to GTCB’s program in human serum albumin, which is extremely promising but must be devalued by half because it is already partnered 50/50 with Fresenius. Regards, Dew
Market Data 
Markets 
AI
